Beijing-based BioGeometry gets $100M+ for AI drug R&D

BioGeometry, a four-year-old Beijing-based biotech company, announced Wednesday that it has raised more than $100 million in Series A funding to advance its AI-driven protein design platform, according to a statement reported by Endpoints News.

The round positions BioGeometry among a growing cohort of companies applying machine learning methods to the structural design of proteins, an approach that has drawn increasing investor interest as computational tools for modeling molecular structures have matured. The company’s work focuses on using artificial intelligence systems to design proteins for drug research and development, according to the report.

Endpoints News did not, in the material reviewed, specify the identities of the round’s investors, the valuation attached to the raise, or the specific therapeutic areas BioGeometry intends to pursue with the new capital. The statement did confirm the headquarters location and the age of the company, placing its founding roughly four years prior to this announcement.

The deal adds to a string of large financings flowing into Chinese biotech firms working at the intersection of artificial intelligence and drug discovery, a sector that has seen sustained capital commitments as firms compete to build computational platforms capable of generating novel protein structures and candidate therapeutics more quickly than traditional laboratory methods allow.

Further details on the round’s structure and participants were not included in the available reporting.